GSK 2816126

Drug Profile

GSK 2816126

Alternative Names: GSK-2816126

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action EZH2 enzyme inhibitors; Histone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma; Follicular lymphoma
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 27 Jul 2017 GlaxoSmithKline terminates a phase I trial in Diffuse large B cell lymphoma and Follicular lymphoma (Second-line therapy or greater) in France, USA and United Kingdom as the maximal dose and schedule attained with GSK 2816126 showed insufficient evidence of clinical activity, and did not justify further clinical investigation (IV) (NCT02082977)
  • 08 Feb 2017 Phase-I clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in France (IV) before February 2017 (NCT02082977)
  • 08 Feb 2017 Phase-I clinical trials in Follicular lymphoma (Second-line therapy or greater) in France (IV) before February 2017 (NCT02082977)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top